In April 2005 the US Food and Drugs Administration (FDA) approved a synthetic version, called exenatide, to treat type 2 diabetic patients unable to sufficiently control their blood sugar levels with other diabetic medications like metformin, and sulfonylureas
The gaps in evaluation were striking: This does not mean telehealth is inherently unsafe
J Clin Endocrinol Metab 2019;104:2463-72.ArticlePubMed 43
With ongoing research and clinical advancements, retatrutide holds significant potential in enhancing health outcomes and transforming lives
Many of these emerging players are based in China, indicating a potential shift in market dynamics unless major licensing or acquisition deals occur
Describing herself as largely 'the lab rat' when she joined the diabetes team, Knudsen remembers she spent 'the first year in a cold room with three technicians to screen hundreds of thousands of compounds to see if they could wedge into the GLP-1 receptor and other targets of interest just snugly enough to stimulate insulin secretion.' To help speed up the screening process, Knudsen devised a method to test 96 candidates in one go instead of just one
